Q&A With Chris Cannon From Brigham & Women's Hospital: Looking At PCSK9 Medications For Patients With Chronic Kidney Disease And Beyond
As more is learned about the affect of newly developed PCSK9 medications cardiologists are looking at new patient populations and how to provide them the highest quality care.
As more is learned about the affect of newly developed PCSK9 medications cardiologists are looking at new patient populations and how to provide them the highest quality care.
Chris Cannon, MD, from Brigham & Women's Hospital discussed both the successes of the new medication as well as some of the questions and challenges that have been posed since its approval at the American Heart Association's annual scientific sessions in Orlando.
One of the biggest questions with new medications is what the proper dosage is for patients. A recent study of Alirocumab showed that even the lowest dosage can provide the desired result for a majority of patients.
With the approval of PCSK9 medications there also came some questions about the new drugs. Issues like statin intolerance and neurological impairment.
